ORAL-B
Today, on Global Accessibility Awareness Day (GAAD), Oral-B proudly launches the Disability Champions Award Programme as part of its ongoing mission to make oral care more accessible to everybody. In partnership with the iADH, the programme aims to make the dentist office experience across Europe more inclusive and positive for those with disabilities and their caregivers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240515281762/en/
Benjamin Binot, P&G Europe Oral Care Senior Vice President, announcing the launch of the Disability Champions Awards Programme and previewing the new iO2 toothbrush at Oral-B’s ‘Championing the Perfect Clean for All’ event in Amsterdam. (Photo: Business Wire)
Over a third (36%) of people with visible and non-visible disabilities feel anxious or frustrated when it comes to visiting the dentist. For instance, individuals with Autism Spectrum Disorder may experience heightened anxiety in unfamiliar environments such as a dental practice, as it disrupts their normal routine. Similarly, a patient with Cerebral Palsy, who may face motor challenges without intellectual disability, might find it difficult to brush their teeth effectively due to limitations in fine motor coordination.
To help overcome this, the Disability Champions Award Programme encourages one member of each dental practice across Europe to become the personal lead to ensure their practice is committed to be more disability positive – because sometimes all it takes is one person to truly make a difference.
By completing the necessary online training and accessibility suggestions devised by iADH and Oral-B (available at https://www.iadh.org/oral-b-iadh-disability-champions/) dental staff who meet the requirements will earn their Disability Champions award. They receive a badge that can be used within their office or on social media to encourage others to become Disability Champions. Their practice will also be visible on Oral-B’s website to make it easier for people with disabilities and their caregivers to find disability positive dental practices near them, and to feel more confident and encouraged about visiting the dentist.
Benjamin Binot, P&G Europe Oral Care Senior Vice President, said: “Last year, we launched The Big Rethink initiative in partnership with iADH to rethink how Oral-B can make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between. This year, we are making our intention good by driving action amongst dental practitioners with the Disability Champions Awards Programme. With our long-term partners, the iADH, we have devised a programme that is straightforward for dental staff to undertake and promote, and that demonstrates their commitment to raising the standard of oral care for people with disabilities.”
Professor. Pedro Diz Dios, President Elect of iADH, said: “At the iADH, we are about promoting equitable oral care. However, we often find that dental practitioners have pre-conceived notions of what makes their practice inclusive, accessible, and positive for people with disabilities and their caregivers. We want to help dentists rethink how to provide a better service for all and believe that appointing one person in the organization to become a Disability Champion will help drive the right change forward. The hope is that as many dental practices as possible across Europe take part in the Disability Champions Award Programme and make better oral care for all a reality.”
The Disability Champions Awards Programme is being launched at Oral-B’s ‘Championing the Perfect Clean for All’ global event being held in Amsterdam between 15-16th May. Over 100+ media, dental professionals and people with disabilities will learn more about the programme, hear inspiring stories from the latest Disability Champions, and experience first-hand how Oral-B plans to bring a better oral care experience to people with disabilities - at the dentist practice and at home. Indeed, Oral-B is previewing its new Oral-B iO2 toothbrush that will bring its revolutionary iO technology to a wider audience, including people with disabilities.
The iO2 is crafted to effortlessly transition manual toothbrush users to electric toothbrushes by bringing Oral-B’s iO technology to life with one simple touch for a simpler, more intuitive cleaning experience that’s tough on plaque and gentle on gums! The dentist-inspired round brush head surrounds teeth, perfectly adapting to their unique shape, removing 100% more bacterial plaque than regular manual brushes even in hard-to-reach areas of the mouth. The iO2 will also come with a new brush head with Smart Bristles that now fully fade their colour to white, making it easy to know when it's time to change your brush head.
1 The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy
Notes to editor:
- About the research: The Oral Health & Disability European Study (2022) surveyed 5,000 respondents across UK, France, Germany and Italy, and was conducted by Reputation Leaders on behalf of Oral-B
- For more information on The Disability Champions Awards Programme, please visit here. The website offers relevant and helpful content for people with disabilities, their caregivers, and families, as well as the professional community.
- Please contact your local Oral-B press office for more information and on local availability of iO2
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bold®, Braun®, Daz®, Fairy®, Febreze®, Gillette®, Head & Shoulders®, Herbal Essences®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, Tampax®, Venus® and Vicks®.
Although headquartered in the US, P&G was founded by an Englishman and an Irishman in 1837, our heritage lives on through the work of Research & Development Centres, Manufacturing Plants and Business sites, across the UK & Ireland.
Beyond our Purpose, Values & Principles, the foundation on which P&G was built and our guiding force for over 180 years, we aspire to be a force for growth so that we can be a force for growth in the communities in which we live and work. Through our citizenship priorities, we want to build a better world for all of us - inside and outside of P&G - free from gender bias, with equal voice and equal representation. Environmental sustainability is embedded into our business, and has been for decades, and we have a strong track record of delivering on our goals in this area. We support communities around the world through our people, our brands and our partners by delivering the comforts of home, health and hygiene.
About Oral-B
Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.
About the International Association for Disability and Oral Health (iADH)
The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, research, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515281762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
